Envafolimab (KN035), TRACON has rights to develop and commercialize envafolimab in sarcoma in North America.
Undifferentiated Pleomorphic Sarcoma (UPS)/Myxofibrosarcoma (MFS) in the U.S.
ENVASARC PHASE 2 (PIVOTAL)
Gastric Cancer (in China)
MSI-H Advanced Solid Tumors (in China)
Biliary Tract Cancer (in China)
PHASE 1 Envafolimab and Doxorubicin
Advance Localized Lung Cancer
1 Strategic partnership with 3D Medicines and Alphamab Oncology
2 Strategic partnership with Eucure Biopharma
3 Strategic partnership with I-Mab Biopharma